Bibliography
- Stevens MFG, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative dacarbazine. Cancer Res 1987;47:5846-52
- Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045; M & B 39381: NSC 362856). Br J Cancer 1992;65:287-91
- Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999;5(8):2192-7
- Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11
- Schering Corporation. Temodar® Product Information, 2008
- Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23(1):35-61
- Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Can Res 2000;6(7):2585-97
- Agarwala S, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51
- Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4
- Hegi ME, Diserens AC, Gorlia T, et al. MGMT Gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
- Middleton MR, Lunn JM, Morris C, et al. O6-Methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78(9):1199-202
- Lee SM, Thatcher N, Crowther D, et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69(3):452-6
- Gerson SL, Spiro TP, Reidenberg P, et al. Rapid depletion of O6-alkylguanine-DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:178a
- Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58(19):4363-7
- Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide [abstract]. Proc Am Soc Clin Oncol 1995;14:1485a
- Accessed from: http://www.cancer.gov/cancertopics/druginfo/fda-temozolomide
- Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17(9):2762-71
- Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20(5):1375-82
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
- Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93
- Hart MG, Grant R, Garside R, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008;4:CD007415
- Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in pediatric patients with advanced cancer. Br J Cancer 1998;78:652-61
- Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A Report from the Children's Cancer Group. J Clin Oncol 1998;16:3037-43
- Carter CA, Waud WR, Plowman J. Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide [abstract]. Proc Am Assoc Cancer Res 1994;35:297
- Hwu WJ, Ayala AE, Hernandez IM. Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Onc Rev 2008;2:168-78
- Bleehen NM, Newlands ES, Lee SM, et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13(4):910-3
- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66
- Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032) [abstract]. Ann Oncol 2008;19(Suppl 8):649
- Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003;39:1271-6
- Kouroussis C, Vamvakas L, Vardakis N, et al. Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: A phase II study. Oncology 2009;76:112-7
- Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and lepto meningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008;10:199-207
- Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide in central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8
- Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7
- Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590-7
- Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113:2524-31
- Tani M, Fina M, Alinari L, et al. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica 2005;90(9):1283-4
- Omuro AM, Taillandier L, Chino O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007;85(2):207-11
- Dario A, Tomei G. The safety of the temozolomide in patients with malignant glioma. Curr Drug Saf 2006;1:205-22
- Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22(4):610-6
- Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005;23(18):4235-6
- Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-7
- Sampson JH, Archer GE, Villavicencio AT, et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999;5:1183-8
- Heimberger AB, Archer GE, McLendon RE, et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2000;6:4148-53